Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers.
Ana Fernández MontesNieves Martínez LagoMarta Covela RúaJuan de la Cámara GómezPaula González VillaroelJosé Carlos Méndez MéndezMónica Jorge FernándezMercedes Salgado FernándezMargarita Reboredo LópezGuillermo Quintero AldanaMaría Luz Pellón AugustoBegoña Graña SuárezJesús García GómezPublished in: Cancer medicine (2019)
Efficacy with FOLFIRI-aflibercept in a real-life population was in line with results from the pivotal trial and toxicity was manageable with treatment adaptation. Survival outcomes were not impacted by primary tumour location, RAS-mutant status, first-line treatment or primary tumour surgery. Hypertension may be a surrogate marker of efficacy in this patient population.